Himalaya Therapeutics: Brian Zhang
Himalaya Therapeutics, a clinical-stage biopharmaceutical company with operations in California and Hong Kong, has appointed Brian Zhang, Ph.D, as CEO.
The company focuses on the development and commercialization in Greater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based on the Conditionally Active Biologics (CAB) technology platform.
Dr. Zhang has decades of experience in R&D, overseeing products from discovery to commercialization. On the corporate side, he has experience leading and founding healthcare companies; and on the investment side, as a venture partner and an angel investor.
During his time at Hoffmann-La Roche, he helped lead the development of Xenical and the discovery of Dorzagliatin, among others, and helped establish its bioinformatics group. More recently, he cofounded several biotechnology startups and invested in biopharmaceuticals.
He received his Ph.D. from the UCLA School of Medicine and his B.S. from Nanjing University. He also conducted brain research at the Chinese Academy of Sciences, earning a grant for further study abroad.